Clinical signs and symptoms associated with increased risk for thrombosis in patients with paroxysmal nocturnal hemoglobinuria from a Korean Registry

被引:92
作者
Lee, Jong Wook [1 ]
Jang, Jun Ho [2 ]
Kim, Jin Seok [3 ]
Yoon, Sung-Soo [4 ]
Lee, Je-Hwan [5 ]
Kim, Yeo-Kyeoung [6 ]
Jo, Deog-Yeon [7 ]
Chung, Jooseop [8 ]
Sohn, Sang Kyun [9 ]
机构
[1] Catholic Univ Korea, Div Hematol, Seoul St Marys Hosp, Coll Med, Seoul 137701, South Korea
[2] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Div Hematol Oncol, Seoul, South Korea
[3] Yonsei Univ, Coll Med, Div Hematol, Seoul, South Korea
[4] Seoul Natl Univ, Coll Med, Div Hematol Oncol, Seoul, South Korea
[5] Univ Ulsan, Coll Med, Div Hematol, Seoul, South Korea
[6] Chonnam Natl Univ, Sch Med, Div Hematol Oncol, Kwangju, South Korea
[7] Chungnam Natl Univ, Sch Med, Div Hematol Oncol, Taejon, South Korea
[8] Pusan Natl Univ, Sch Med, Div Hematol Oncol, Pusan 609735, South Korea
[9] Kyungpook Natl Univ, Sch Med, Div Hematol Oncol, Taegu, South Korea
关键词
Risk factor; Hemolysis; Thrombosis; Mortality; Paroxysmal nocturnal hemoglobinuria; COMPLEMENT INHIBITOR ECULIZUMAB; NATURAL-HISTORY; APLASTIC-ANEMIA; NITRIC-OXIDE; HEMOLYSIS; MANAGEMENT; DIAGNOSIS; PRESSURE; DISEASE; SAFETY;
D O I
10.1007/s12185-013-1346-4
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Paroxysmal nocturnal hemoglobinuria (PNH) is characterized by chronic, complement-mediated hemolysis, frequently leading to debilitating clinical symptoms and life-threatening complications such as thromboembolism (TE). A retrospective analysis was performed on 301 patients from the South Korean National PNH Registry to describe disease burden and identify TE-associated risk factors. TE was identified in 18 % of patients and was associated with increased risk for mortality [odds ratio (OR), 6.85; P < 0.001]. A multivariate analysis showed that PNH patients with elevated hemolysis [lactate dehydrogenase (LDH) levels a parts per thousand yen1.5 times the upper limit of normal (ULN)] at diagnosis were at significantly higher risk for TE than patients with LDH < 1.5 x ULN (OR 7.0; P = 0.013). The combination of LDH a parts per thousand yen1.5 x ULN with the clinical symptoms of abdominal pain, chest pain, dyspnea, or hemoglobinuria was associated with a greater increased risk for TE than elevated hemolysis or clinical symptoms alone. Continuous monitoring of these risk factors is critical for identifying PNH patients at risk for morbidities and mortality and allowing early intervention. (clinicaltrials.gov identifier: NCT01224483).
引用
收藏
页码:749 / 757
页数:9
相关论文
共 33 条
  • [1] Gastrointestinal involvement in paroxysmal nocturnal hemoglobinuria - First report of electron microscopic findings
    Adams, T
    Fleischer, D
    Marino, G
    Rusnock, E
    Li, L
    [J]. DIGESTIVE DISEASES AND SCIENCES, 2002, 47 (01) : 58 - 64
  • [2] INTESTINAL INFARCTION IN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA
    BLUM, SF
    GARDNER, FH
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1966, 274 (20) : 1137 - &
  • [3] Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria
    Brodsky, Robert A.
    Young, Neal S.
    Antonioli, Elisabetta
    Risitano, Antonio M.
    Schrezenmeier, Hubert
    Schubert, Jorg
    Gaya, Anna
    Coyle, Luke
    De Castro, Carlos
    Fu, Chieh-Lin
    Maciejewski, Jaroslaw P.
    Bessler, Monica
    Kroon, Henk-Andre
    Rother, Russell P.
    Hillmen, Peter
    [J]. BLOOD, 2008, 111 (04) : 1840 - 1847
  • [4] Paroxysmal nocturnal hemoglobinuria:: natural history of disease subcategories
    de Latour, Regis Peffault
    Mary, Jean Yves
    Salanoubat, Celia
    Terriou, Louis
    Etienne, Gabriel
    Mohty, Mohamad
    Roth, Sophie
    de Guibert, Sophie
    Maury, Sebastien
    Cahn, Jean Yves
    Socie, Gerard
    [J]. BLOOD, 2008, 112 (08) : 3099 - 3106
  • [5] Doukas MA, 1984, AM J HEMATOL, V161, P75
  • [6] Primary prophylaxis with warfarin prevents thrombosis in paroxysmal nocturnal hemoglobinuria (PNH)
    Hall, C
    Richards, S
    Hillmen, P
    [J]. BLOOD, 2003, 102 (10) : 3587 - 3591
  • [7] Sustained response and long-term safety of eculizumab in paroxysmal nocturnal hemoglobinuria
    Hill, A
    Hillmen, P
    Richards, SJ
    Elebute, D
    Marsh, JC
    Chan, J
    Mojcik, CF
    Rother, RP
    [J]. BLOOD, 2005, 106 (07) : 2559 - 2565
  • [8] Hill A, 2005, HAEMATOLOGICA S, V9012, P40
  • [9] Under-recognized complications in patients with paroxysmal nocturnal haemoglobinuria: raised pulmonary pressure and reduced right ventricular function
    Hill, Anita
    Sapsford, Robert J.
    Scally, Andrew
    Kelly, Richard
    Richards, Stephen J.
    Khurisgara, Gus
    Sivananthan, Mohan U.
    Hillmen, Peter
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2012, 158 (03) : 409 - 414
  • [10] Effect of eculizumab on haemolysis-associated nitric oxide depletion, dyspnoea, and measures of pulmonary hypertension in patients with paroxysmal nocturnal haemoglobinuria
    Hill, Anita
    Rother, Russell P.
    Wang, Xunde
    Morris, Sidney M., Jr.
    Quinn-Senger, Kerry
    Kelly, Richard
    Richards, Stephen J.
    Bessler, Monica
    Bell, Leonard
    Hillmen, Peter
    Gladwin, Mark T.
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2010, 149 (03) : 414 - 425